A Prospective, Multicenter Trial on the Efficacy and Safety of Poly-L-lactic Acid (Sculptra® Aesthetic) for the Treatment of Contour Deformities of the Buttocks Region

Erevna Innovations Inc.1 site in 1 country30 target enrollmentApril 8, 2019

ConditionsButtock Contouring Buttock Lifting

Overview

Phase: Phase 4
Intervention: Not specified
Conditions: Buttock Contouring
Sponsor: Erevna Innovations Inc.
Enrollment: 30
Locations: 1
Primary Endpoint: Percentage of subjects to achieve a one-point increase or higher since Baseline, on the Global Aesthetic Improvement Scale (GAIS) at Visit 6
Status: Completed
Last Updated: 6 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

This is a phase IV prospective, multicentre, single cohort, open-label clinical trial evaluating the efficacy and safety of Poly-L-lactic acid (Sculptra® Aesthetic) for the treatment of contour deformities of the buttocks region

Registry

clinicaltrials.gov

Start Date

April 8, 2019

End Date

March 8, 2020

Last Updated

6 years ago

Study Type

Interventional

Study Design

Single Group

Sex

Female

Investigators

Sponsor

Erevna Innovations Inc.

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Age between 30 and 60 years;
•Indication for treatment of bilateral contour deformities;
•Mild to moderate flaccidity in the area to be treated, according to investigator's assessment;
•An intact immune system, as the bio-stimulatory effect of Sculptra® Aesthetic is dependent on the host response. An intact immune system, as the bio-stimulatory effect of Sculptra® Aesthetic is dependent on the host response. Immune function will be evaluated through clinical history. Exclusions will consist of both primary (genetic) and secondary (acquired) immune deficiencies. Examples include: HIV/AIDS, chemotherapy, cancers (e.g., leukemia and lymphoma), certain autoimmune diseases (e.g., myasthenia gravis, systemic lupus erythematosus), certain medications (e.g., corticosteroids, tumor necrosis factor inhibitors, anticonvulsants), and certain chronic or congenital diseases. Any type of comorbidity or clinical condition will be reviewed at the investigator's discretion.
•. Subjects who understood and signed the Informed Consent Form (ICF) when entering the study, before performing any investigational procedure.

Exclusion Criteria

•Prior (i.e., \<1 year) or planned use (for the duration of the study period) any other aesthetic treatment in the buttock region, such as radiofrequency, cryolipolysis, dermal subscision, plastic surgery, laser treatment, chemical peeling or any other procedure based on active dermal response;
•Any type of comorbidity or clinical condition that, at investigator's discretion, could interfere with study assessments;
•Using or planning to initiate restrictive diets (at investigator's discretion);
•Using or planning to initiate use of supplements for weight loss;
•Diabetes mellitus type 1 or type 2;
•Autoimmune diseases, collagenosis, decompensated endocrine diseases or any disease that, at investigator's discretion, could interfere with study assessments;
•Using or have used within the previous 3 months drugs such as corticosteroids, immunosuppressants, anticoagulants or other collagen-production inhibitors;
•Initiated use of hormones or change in dose of hormonal replacement therapy within 3 months;
•Practices regularly or intend to practice during the study high-performance or impact physical activities, such as weight lifting, marathon, triathlon;
•Pregnant or breastfeeding, or wishes to get pregnant within the next 18 months, or refuses to use appropriate contraceptive method (in case of women of childbearing potential);

Outcomes

Primary Outcomes

Percentage of subjects to achieve a one-point increase or higher since Baseline, on the Global Aesthetic Improvement Scale (GAIS) at Visit 6

Time Frame: Month 6

Secondary Outcomes

Assessment of adverse events (AEs) at all study visits (Visits 0-6). The incidence, seriousness, severity and relationship with the medical device of AEs reported will be evaluated.(All visits, Baseline to Month 6)